Enliven Therapeutics (NASDAQ:ELVN) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of Enliven Therapeutics (NASDAQ:ELVN) from a strong sell rating to a hold rating in a research report report published on Wednesday morning,Zacks reports.

ELVN has been the subject of several other reports. JPMorgan Chase & Co. assumed coverage on shares of Enliven Therapeutics in a research report on Thursday, October 1st. They issued an “overweight” rating and a $75.00 price objective for the company. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. The Goldman Sachs Group lifted their price target on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Mizuho boosted their price target on Enliven Therapeutics from $62.00 to $73.00 and gave the company an “outperform” rating in a report on Tuesday, August 18th. Finally, Morgan Stanley began coverage on Enliven Therapeutics in a report on Friday, October 2nd. They issued an “overweight” rating and a $70.00 price target for the company. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Enliven Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $75.44.

Enliven Therapeutics Trading Down 5.6%

Shares of ELVN opened at $48.31 on Wednesday. The firm has a market capitalization of $3.56 billion, a P/E ratio of -28.25 and a beta of 0.34. Enliven Therapeutics has a 12-month low of $14.78 and a 12-month high of $62.32. The firm has a fifty day moving average price of $46.65 and a 200-day moving average price of $43.56.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.09. Analysts predict that Enliven Therapeutics will post -1.70 earnings per share for the current year.

Insider Activity

In related news, Director J. Scott Garland sold 13,000 shares of Enliven Therapeutics stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $46.67, for a total value of $606,710.00. Following the completion of the sale, the director directly owned 13,000 shares in the company, valued at $606,710. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Benjamin Hohl sold 6,018 shares of the company’s stock in a transaction dated Monday, October 19th. The stock was sold at an average price of $38.48, for a total transaction of $231,572.64. Following the completion of the sale, the chief financial officer directly owned 38,000 shares of the company’s stock, valued at approximately $1,462,240. This trade represents a 13.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 31,054 shares of company stock valued at $1,493,823 over the last 90 days. 3.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds have recently modified their holdings of ELVN. BlackRock Inc. purchased a new position in Enliven Therapeutics during the second quarter valued at approximately $221,255,000. First Light Asset Management LLC lifted its holdings in Enliven Therapeutics by 574.1% during the second quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company’s stock worth $69,058,000 after buying an additional 1,158,883 shares during the period. Pictet Asset Management Holding SA lifted its holdings in Enliven Therapeutics by 14.1% during the third quarter. Pictet Asset Management Holding SA now owns 1,325,740 shares of the company’s stock worth $60,772,000 after buying an additional 163,956 shares during the period. Assenagon Asset Management S.A. boosted its position in Enliven Therapeutics by 276.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,153,973 shares of the company’s stock valued at $52,898,000 after acquiring an additional 847,399 shares in the last quarter. Finally, Rock Springs Capital Management LP boosted its position in Enliven Therapeutics by 3.5% during the 1st quarter. Rock Springs Capital Management LP now owns 826,500 shares of the company’s stock valued at $32,399,000 after acquiring an additional 28,095 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. Its research centers on precision oncology, with drug candidates designed to target specific proteins involved in tumor growth. The company’s pipeline has included ELVN-001, an investigational BCR-ABL1 inhibitor being studied for chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor developed for cancers driven by HER2. Enliven is based in Boulder, Colorado.